Discovery of MK-1088 as a Potent A 2A /A 2B Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy

Key Points

• To investigate the potential of MK-1088 as a dual-antagonist for A2A and A2B adenosine receptors in cancer treatment.
• Identification of MK-1088 as a candidate drug
• Evaluation of its antagonistic properties on A2A and A2B receptors
• Analysis of its effects on cancer immune response
• MK-1088 demonstrated potent dual-antagonistic activity
• Progression to human clinical studies is now underway